-+ 0.00%
-+ 0.00%
-+ 0.00%

B of A Securities Initiates Coverage On Iambic Therapeutics with Buy Rating, Announces Price Target of $30

Benzinga·11/09/2026 11:56:42
Listen to the news
B of A Securities analyst Alec Stranahan initiates coverage on Iambic Therapeutics (NASDAQ:IAM) with a Buy rating and announces Price Target of $30.